Tuncer 2003.

Methods	Randomised clinical trial
Participants	Country: Turkey Number randomised: 53 Post‐randomisation dropouts: 0 Revised sample size: 53 Average age: 46 years Females: 19 (35.8%) Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): both Alcohol‐related cirrhosis: not stated Viral‐related cirrhosis: both Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated Other causes for cirrhosis: both Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated Follow‐up in months: 0.25 Years of recruitment: not stated Exclusion criteria Hypersensitivity to quinolones or cephalosporins Recent antibiotic use Systemic infections Secondary peritonitis
Interventions	Participants were randomly assigned to three groups. Group 1: cirpofloxacin (n = 16) Further details: ciprofloxacin 500 mg oral twice/day for 5 days Group 2: cefotaxime (n = 18) Further details: cefotaxime 2 g IV three times/day for 5 days Group 3: ceftriaxone (n = 19) Further details: ceftriaxone 2 g/day IV for 5 days
Outcomes	Outcome reported Mortality Any adverse events ( number of people) Proportion with recovery from SBP Other features of decompensation Treatment costs
Notes	Attempts were made to contact the authors in December 2018; there were no replies. Follow‐up information was not available but the follow‐up was probably until the end of hospitalisation. Although the authors excluded 3 patients from the analysis, these have been included for all outcomes other than complications and decompensated cirrhosis.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: all patients were included in the analysis of mortality and SBP resolution. There were post‐randomisation dropouts related to the treatment and outcome for remaining outcomes; therefore risk of bias is high for these outcomes.
Selective reporting (reporting bias)	Low risk	Comment: a prepublished protocol was not available but the authors report routinely measured clinical outcomes adequately.
Other bias	Low risk	Comment: no other bias was noted.